This medicine was approved on 19 December 2017 and is manufactured by Spark Therapeutics, Inc. It is administered as a subretinal injection in the form of a suspension and is specifically indicated for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, including certain forms of RP [46] (Figure 1). This evidence concerns the gene RPE65 and Retinal dystrophy.